AB185. Therapeutic potential of adipose-derived stem cells-based micro-tissues in a rat model of stress urinary incontinence
Animal Study with a reported sample of 3, published in Transl Androl Urol (2015) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Transl Androl Urol (2015)
- Reported sample size
- 3
- Source database
- Europe PMC
- PMCID
- PMC4708737
Abstract (original English)
Objective Using adipose-derived stem cells (ADSCs) to halt stress urinary incontinence (SUI) progression and regenerate urethral sphincter (US) has emerged as a promising method to restore normal voiding function. However, traditional two-dimensional (2D) cell culture systems have limitations in mimicking in vivo conditions losing some important properties. This study aims to examine the potential and mechanism of three-dimensional (3D) cultures of ADSCs in the treatment of SUI in a rat model simulating childbirth injury. Methods ADSCs were used to generate micro-tissues (MTs) with a hanging drop method. A total of 48 postpartum Sprague-Dawley (SD) rats were developed SUI models by 4 h vagina dilation (VD) followed by bilateral ovariectomy (OV). Ten rats underwent sham OV without VD as control group. The SUI rats were divided into three groups and received urethral injection of PBS, ADSCs and MTs. specimens were harvested for histology and tracking CM-Dil-Labelled ADSCs at day 1, 3, 7 (n=3), and 28 (n=7) post-injection. At day 28, the remaining rats in each group were examined for voiding function. Western blot, immunofluorescence (IF) and immunohistochemistry (IHC) staining were performed to examine the histological change and cytokines. Results Compared with ADSCs, MTs expressed increased vascular endothelia growth factor (VEGF), TNFα stimulated gene/protein 6 (TSG-6) in vitr
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.